Unicycive Therapeutics filings document the regulatory, financing, governance, and operating disclosures of a Nasdaq-listed clinical-stage biotechnology company focused on kidney disease therapies. Form 8-K reports furnish financial results and business updates, including disclosures related to oxylanthanum carbonate, NDA activity, manufacturing matters, and the company’s cash and capital resources.
The filing record also covers common stock registered on the Nasdaq Capital Market, emerging growth company status, at-the-market equity sales under a shelf registration statement, and board and executive-governance matters. Proxy materials document director elections, auditor ratification, stockholder voting mechanics, and annual meeting procedures, while other current reports address securities litigation risk tied to public statements about the OLC program.
Unicycive Therapeutics, Inc. reports that RA Capital Management, L.P., RA Capital Healthcare Fund, L.P., Peter Kolchinsky and Rajeev Shah beneficially own 2,801,082 shares of Common Stock as of March 31, 2026, representing 9.99% under a disclosed ownership blocker. The filing states the Fund holds Tranche A, B and C warrants convertible into 1,097,325, 997,568 and 1,596,109 common shares respectively, but conversion is limited by a Beneficial Ownership Blocker that prevents ownership above 9.99%. Shares outstanding used for the percentage calculation were 25,237,782 shares as of March 30, 2026.
Unicycive Therapeutics reported a significantly wider loss for the first quarter of 2026, driven mainly by non-cash warrant valuation effects. Net comprehensive loss attributable to common stockholders was $12.8 million, or $(0.54) per share, compared with $0.5 million, or $0.04 per share, a year earlier.
Operating expenses were modestly higher at $8.4 million, as lower R&D spending of $1.6 million was offset by higher G&A of $6.8 million. The swing in other income to a $4.4 million expense from $8.6 million income was primarily due to an increase in the fair value of the warrant liability. As of May 11, 2026, cash, cash equivalents, and marketable securities totaled $57.1 million, which the company believes will fund planned operations into 2027.
Management highlighted preparations for the potential launch of oxylanthanum carbonate (OLC), its lead phosphate binder candidate, ahead of the June 29, 2026 PDUFA target action date for FDA review in hyperphosphatemia in dialysis patients.
Unicycive Therapeutics, Inc. is asking stockholders to vote at its June 19, 2026 annual meeting on two main items: electing three directors (Shalabh Gupta, M.D., Sandeep Laumas, M.D., and Saraswati Kenkare‑Mitra, Ph.D.) and ratifying Grassi & Co. CPAs, P.C. as auditor for 2026.
Stockholders of record at the close of business on April 27, 2026, when 26,700,027 common shares were outstanding, are entitled to one vote per share. A majority of these shares, or 13,341,637, is needed for a quorum. The Board currently has a combined Chair/CEO structure, with Gupta serving as both.
The proxy describes Nasdaq independence determinations, committee structures and recent resignation of independent director Gaurav Aggarwal, M.D., with plans to appoint a new independent director and committee member by October 3, 2026 under Nasdaq grace periods. It also outlines executive pay, including 2025 total compensation of $2,391,621 for the CEO, largely from option awards, and severance and change‑in‑control protections.
Unicycive Therapeutics, Inc. reported that director Gaurav Aggarwal resigned from its Board of Directors effective April 6, 2026.
The company stated that his resignation was not due to any disagreement with management or the Board regarding operations, policies, or practices and expressed gratitude for his service.
Unicycive Therapeutics reported narrower losses for the year ended December 31, 2025 and highlighted regulatory progress for its lead kidney-disease drug candidate. Research and development spending fell to $9.1 million from $20.0 million as major clinical work wound down, while general and administrative costs rose to $20.4 million from $12.1 million due to consulting, professional services, and commercial launch preparation.
Net loss attributable to common stockholders improved to $26.6 million, or $1.67 per share, from $37.8 million, or $5.65 per share, helped by lower R&D and a favorable warrant liability revaluation that turned other income to $3.0 million from a $4.6 million expense. As of March 30, 2026, unaudited cash, cash equivalents, and marketable securities totaled $54.9 million, and the company states it can fund planned operations into 2027. Management noted that the FDA has accepted its New Drug Application resubmission for oxylanthanum carbonate (OLC) for hyperphosphatemia in dialysis patients, with the potential for approval and launch later in 2026.
Unicycive Therapeutics’ annual report outlines its kidney-focused drug pipeline, regulatory progress, and commercial plans. The company’s lead candidate, oxylanthanum carbonate (OLC), targets hyperphosphatemia in dialysis patients and is being reviewed via the 505(b)(2) pathway. After a Complete Response Letter tied to a third-party manufacturer, Unicycive resubmitted its OLC NDA in December 2025; the FDA accepted it as a Class II resubmission with a new PDUFA target action date of June 29, 2026. The report describes positive Phase 2 tolerability data and bioequivalence to Fosrenol, along with a concentrated U.S. launch strategy focused on large dialysis organizations and high-prescribing nephrologists. A second program, UNI-494 for acute kidney injury and delayed graft function, has orphan drug designation but further development has been deprioritized while the company focuses on OLC commercialization.
Unicycive Therapeutics, Inc. has a new large shareholder disclosure. RA Capital Management, its RA Capital Healthcare Fund and principals Peter Kolchinsky and Rajeev Shah report beneficial ownership of 2,385,279 shares of Unicycive common stock, representing 9.99% of the class as of December 31, 2025.
The position comes through Tranche A, B and C warrants exercisable into preferred stock series that are convertible into common shares, all subject to a 9.99% beneficial ownership blocker. The filers certify the holdings are not for the purpose of changing or influencing control of Unicycive.
Unicycive Therapeutics received an updated ownership disclosure showing that Nantahala Capital Management, along with Wilmot B. Harkey and Daniel Mack, report beneficial ownership of 2,281,040 shares of common stock, or 9.99% of the company, as of December 31, 2025.
This stake includes 1,341,838 shares that may be acquired within sixty days through the exercise of convertible securities. The reporting persons share voting and dispositive power over all reported shares and report no sole voting or dispositive authority.
The filing states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. A fund advised by Nantahala, Blackwell Partners LLC – Series A, has rights to dividends and sale proceeds on more than five percent of the outstanding common stock reported here.